Principles of antidote pharmacology: An update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents

British Journal of Pharmacology

Volumn 161, Issue 4, 2010, Pages 721-748

  Ramasamy, S ^a   Liu, C Q ^a   Tran, H ^a   Gubala, A ^a   Gauci, P ^a   McAllister, J ^a   Vo, T ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

anthrax; biological; botulism; cholera; encephalitis; melioidosis; plague; Q fever; ricin; smallpox

Indexed keywords

AMOXICILLIN; AMPLIGEN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIBODY; ANTIDOTE; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; CEFOPERAZONE; CHOLERA VACCINE; CHOLERAGARDE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; IMIPENEM; IMMUNOMODULATING AGENT; MEROPENEM; MUTACHOL; NUCLEIC ACID; PLAGUE VACCINE; Q FEVER VACCINE; RIBOZYME; RICIN; SMALLPOX VACCINE; SULBACTAM; SULFAMETHOXAZOLE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ANTHRAX; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACILLUS ANTHRACIS; BACTERIOPHAGE; BIOLOGICAL WARFARE; BOTULISM; BURKHOLDERIA PSEUDOMALLEI; CHOLERA; CLINICAL FEATURE; CLINICAL PROTOCOL; CLOSTRIDIUM BOTULINUM; COXIELLA BURNETII; ENVIRONMENTAL EXPOSURE; FOOD AND DRUG ADMINISTRATION; HISTORY; HUMAN; INTOXICATION; MACULOPAPULAR RASH; MELIOIDOSIS; MICROENCAPSULATION; NONHUMAN; PLAGUE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; Q FEVER; REVIEW; RICIN INTOXICATION; RISK ASSESSMENT; SKIN MANIFESTATION; SMALLPOX; SMALLPOX VIRUS; TERRORISM; TOGAVIRUS; VACCINATION; VENEZUELAN EQUINE ENCEPHALITIS; VIBRIO CHOLERAE; VIRUS ENCEPHALITIS; VIRUS TRANSMISSION; WESTERN EQUINE ENCEPHALITIS; WORLD HEALTH ORGANIZATION; YERSINIA PESTIS;

EID: 77957228927     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00939.x     Document Type: Review

References (237)

1. Aguilar PV, Weaver SC, Basler CF (2007). Capsid protein of eastern equine encephalitis virus inhibits host cell gene expression. J Virol 81 : 3866 3876.
2. Aguilar PV, Adams AP, Wang E, Kang W, Carrara AS, Anishchenko M et al. (2008a). Structural and nonstructural protein genome regions of eastern equine encephalitis virus are determinants of interferon sensitivity and murine virulence. J Virol 82 : 4920 4930. (Pubitemid 351657053)
3. Aguilar PV, Leung LW, Wang E, Weaver SC, Basler CF (2008b). A five-amino-acid deletion of the eastern equine encephalitis virus capsid protein attenuates replication in mammalian systems but not in mosquito cells. J Virol 82 : 6972 6983. (Pubitemid 351977718)
4. Airhart CL, Rohde HN, Bohach GA, Hovde CJ, Deobald CF, Lee SS et al. (2008). Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague. Microbiology 154 (Pt 7 2131 2138.
5. Andrews GP, Heath DG, Anderson GW, Jr., Welkos SL, Friedlander AM (1996). Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64 : 2180 2187.
6. Anh DD, Canh do G, Lopez AL, Thiem VD, Long PT, Son NH et al. (2007). Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25 : 1149 1155.
7. Arlen PA, Singleton M, Adamovicz JJ, Ding Y, Davoodi-Semiromi A, Daniell H (2008). Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun 76 : 3640 3650.
8. Arrigo NC, Watts DM, Frolov I, Weaver SC (2008). Experimental infection of Aedes sollicitans and Aedes taeniorhynchus with two chimeric Sindbis/Eastern equine encephalitis virus vaccine candidates. Am J Trop Med Hyg 78 : 93 97. (Pubitemid 351844501)
9. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T et al. (2005). A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 23 : 3301 3309. (Pubitemid 40523124)
10. Audi J, Belson M, Patel M, Schier J, Osterloh J (2005). Ricin poisoning: a comprehensive review. JAMA 294 : 2342 2351.
11. Aulinger BA, Roehrl MH, Mekalanos JJ, Collier RJ, Wang JY (2005). Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 73 : 3408 3414.
12. Baillie LW, Rodriguez AL, Moore S, Atkins HS, Feng C, Nataro JP et al. (2008). Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy. Vaccine 26 : 6083 6091.
13. Baker EE, Sommer H, Foster LE, Meyer E, Meyer KF (1952). Studies on immunization against plague. I. The isolation and characterization of the soluble antigen of Pasteurella pestis. J Immunol 68 : 131 145.
14. Barabe ND, Rayner GA, Christopher ME, Nagata LP, Wu JQ (2007). Single-dose, fast-acting vaccine candidate against western equine encephalitis virus completely protects mice from intranasal challenge with different strains of the virus. Vaccine 25 : 6271 6276.
15. Barnes JL, Ketheesan N (2007). Development of protective immunity in a murine model of melioidosis is influenced by the source of Burkholderia pseudomallei antigens. Immunol Cell Biol 85 : 551 557. (Pubitemid 47530591)
16. Barnes JL, Williams NL, Ketheesan N (2008). Susceptibility to Burkholderia pseudomallei is associated with host immune responses involving tumor necrosis factor receptor-1 (TNFR1) and TNF receptor-2 (TNFR2). FEMS Immunol Med Microbiol 52 : 379 388. (Pubitemid 351420758)
17. Behbehani AM (1983). The smallpox story: life and death of an old disease. Microbiol Rev 47 : 455 509.
18. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS et al. (2003). Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100 : 9458 9463. (Pubitemid 37033950)
19. Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA et al. (2008). Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 82 : 3517 3529. (Pubitemid 351429927)
20. Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW et al. (2007). Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 75 : 4020 4029. (Pubitemid 47206301)
21. Bina XR, Philippart JA, Bina JE (2009). Effect of the efflux inhibitors 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide on antimicrobial susceptibility and virulence factor production in Vibrio cholerae. J Antimicrob Chemother 63 : 103 108.
22. Blisnick T, Ave P, Huerre M, Carniel E, Demeure CE (2008). Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect Immun 76 : 3808 3816.
23. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A et al. (2004a). Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax. Euro Surveill 9 : E3 E4.
24. Bossi P, Tegnell A, Baka A, van Loock F, Hendriks J, Werner A et al. (2004b). Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism. Euro Surveill 9 : E13 E14.
25. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A et al. (2004c). Bichat guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro Surveill bulletin européen sur les maladies transmissibles = European communicable disease bulletin. 9 : E17 E18.
26. Bouzianas DG (2007). Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism. Expert Rev Anti Infect Ther 5 : 665 684.
27. Brahmbhatt TN, Darnell SC, Carvalho HM, Sanz P, Kang TJ, Bull RL et al. (2007). Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun 75 : 5240 5247. (Pubitemid 350033610)
28. Breitbach K, Kohler J, Steinmetz I (2008). Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans R Soc Trop Med Hyg 102 (Suppl. 1 589 594.
29. Brey RN (2005). Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 57 : 1266 1292.
30. Brook I, Elliott TB, Pryor HI, 2nd., Sautter TE, Gnade BT, Thakar JH et al. (2001). In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 18 : 559 562. (Pubitemid 33152750)
31. Brossier F, Levy M, Mock M (2002). Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 70 : 661 664. (Pubitemid 34083825)
32. Bubeck SS, Dube PH (2007). Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine. Clin Vaccine Immunol 14 : 1235 1238.
33. Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY (2004). Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318 : 474 481. (Pubitemid 38224291)
34. Cai S, Sarkar HK, Singh BR (1999). Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry 38 : 6903 6910. (Pubitemid 129514992)
35. Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A (2007). Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. Clin Infect Dis 45 : 548 555. (Pubitemid 47328633)
36. Carra JH, Wannemacher RW, Tammariello RF, Lindsey CY, Dinterman RE, Schokman RD et al. (2007). Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. Vaccine 25 : 4149 4158.
37. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN (2004). Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 43 : 1503 1510. (Pubitemid 38561324)
38. Challoner KR, McCarron MM (1990). Castor bean intoxication. Ann Emerg Med 19 : 1177 1183.
39. Charles PC, Brown KW, Davis NL, Hart MK, Johnston RE (1997). Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology 228 : 153 160.
40. Cheng AC, Stephens DP, Currie BJ (2003). Granulocyte colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev : CD004400.
41. Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ (2004). Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 48 : 1763 1765.
42. Cheng AC, Currie BJ (2005). Melioidosis: epidemiology, pathophysiology and management. Clinical Microbiology Reviews 18 : 383 416.
43. Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B (2001). Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin Infect Dis 33 : 29 34. (Pubitemid 32554499)
44. Chichester JA, Musiychuk K, de la Rosa P, Horsey A, Stevenson N, Ugulava N et al. (2007). Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 25 : 3111 3114. (Pubitemid 46482745)
45. Chyka PA, Seger D (1997). Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 35 : 721 741.
46. Clements JD, Yancey RJ, Finkelstein RA (1980). Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun 29 : 91 97. (Pubitemid 10085979)
47. Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D et al. (2008). Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 76 : 5588 5597.
48. Cuccui J, Easton A, Chu KK, Bancroft GJ, Oyston PCF, Titball RW et al. (2007). Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis. Infect Immun 75 : 1186 1195. (Pubitemid 46385809)
49. Cybulski RJ, Jr., Sanz P, McDaniel D, Darnell S, Bull RL, O'Brien AD (2008). Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen. Vaccine 26 : 4927 4939.
50. Das D, Nagata LP, Suresh MR (2007). Immunological evaluation of Escherichia coli expressed E2 protein of Western equine encephalitis virus. Virus Res 128 : 26 33. (Pubitemid 47248622)
51. Davis JS, Currie BJ, Fisher DA, Huffam SE, Anstey NM, Price RN et al. (2003). Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. Commun Dis Intell 27 : 526 532.
52. Day PJ, Pinheiro TJ, Roberts LM, Lord JM (2002). Binding of ricin A-chain to negatively charged phospholipid vesicles leads to protein structural changes and destabilizes the lipid bilayer. Biochemistry 41 : 2836 2843.
53. Dembek ZF, Smith LA, Rusnak JM (2007). Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep 1 : 122 134.
54. Dixon TC, Meselson M, Guillemin J, Hanna PC (1999). Anthrax. N Engl J Med 341 : 815 826. (Pubitemid 29420478)
55. Doan LG (2004). Ricin: mechanism of toxicity, clinical manifestations, and vaccine development. A review. J Toxicol Clin Toxicol 42 : 201 208. (Pubitemid 38758534)
56. Drexler I, Heller K, Wahren B, Erfle V, Sutter G (1998). Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79 (Pt 2 347 352. (Pubitemid 28048439)
57. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH et al. (2004). Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428 : 182 185.
58. Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K et al. (2008). Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci USA 105 : 10889 10894.
59. Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ (2007). A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 195 : 99 107. (Pubitemid 44958231)
60. Eyles JE, Butcher WA, Titball RW, Hill J (2007). Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity. Vaccine 25 : 7301 7306. (Pubitemid 47496079)
61. Fan S, Wu F, Martiniuk F, Hale ML, Ellington AD, Tchou-Wong KM (2008). Protective effects of anti-ricin A-chain RNA aptamer against ricin toxicity. World J Gastroenterol 14 : 6360 6365.
62. Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D (2001). Risks factors and prevention of Q fever endocarditis. Clin Infect Dis 33 : 312 316. (Pubitemid 32664833)
63. Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM (2008). Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 26 : 1794 1804.
64. Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, Raetz JL et al. (2007). Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 25 : 1868 1876.
65. Fine DL, Roberts BA, Terpening SJ, Mott J, Vasconcelos D, House RV (2008). Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Vaccine 26 : 3497 3506.
66. Flick-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, Miller J et al. (2002). A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 70 : 1653 1656. (Pubitemid 34163452)
67. Forman S, Wulff CR, Myers-Morales T, Cowan C, Perry RD, Straley SC (2008). yadBC of Yersinia pestis, a new virulence determinant for bubonic plague. Infect Immun 76 : 578 587. (Pubitemid 351251728)
68. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H et al. (2007). Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 25 : 8562 8573.
69. Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF et al. (2008). Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax((R)) in healthy vaccinia-naive adults. Vaccine 27 : 1637 1644.
70. Furbee B, Wermuth M (1997). Life-threatening plant poisoning. Crit Care Clin 13 : 849 888. (Pubitemid 27432896)
71. Furukawa-Stoffer TL, Mah DC, Cherwonogrodzky JW, Weselake RJ (1999). A novel biological-based assay for the screening of neutralizing antibodies to ricin. Hybridoma 18 : 505 511.
72. Garmashova N, Atasheva S, Kang W, Weaver SC, Frolova E, Frolov I (2007). Analysis of Venezuelan equine encephalitis virus capsid protein function in the inhibition of cellular transcription. J Virol 81 : 13552 13565. (Pubitemid 350247849)
73. Glomski IJ, Corre JP, Mock M, Goossens PL (2007). Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J Immunol 178 : 2646 2650. (Pubitemid 46333139)
74. Glynn A, Freytag LC, Clements JD (2005). Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine 23 : 1957 1965. (Pubitemid 40289067)
75. Golden JW, Josleyn MD, Hooper JW (2008). Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 26 : 3507 3515.
76. Golovkin M, Spitsin S, Andrianov V, Smirnov Y, Xiao Y, Pogrebnyak N et al. (2007). Smallpox subunit vaccine produced in Planta confers protection in mice. Proc Natl Acad Sci USA 104 : 6864 6869. (Pubitemid 47175592)
77. Goodin JL, Nellis DF, Powell BS, Vyas VV, Enama JT, Wang LC et al. (2007). Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Expr Purif 53 : 63 79.
78. Greenberg RN, Kennedy JS (2008). ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 17 : 555 564.
79. Griffiths GD, Phillips GJ, Holley J (2007). Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection. Inhal Toxicol 19 : 873 887. (Pubitemid 47237749)
80. Grosenbach DW, Jordan R, King DS, Berhanu A, Warren TK, Kirkwood-Watts DL et al. (2008). Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 26 : 933 946.
81. Guatteo R, Seegers H, Joly A, Beaudeau F (2008). Prevention of Coxiella burnetii shedding in infected dairy herds using a phase I C. burnetii inactivated vaccine. Vaccine 26 : 4320 4328.
82. Gupta M, Alam S, Bhatnagar R (2007). Catalytically inactive anthrax toxin(s) are potential prophylactic agents. Vaccine 25 : 8410 8419. (Pubitemid 350137601)
83. Hackstadt T, Williams JC (1981). Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii. Proc Natl Acad Sci USA 78 : 3240 3244. (Pubitemid 11032023)
84. Haraga A, West TE, Brittnacher MJ, Skerrett SJ, Miller SI (2008). Burkholderia thailandensis as a model system for the study of the virulence-associated type III secretion system of burkholderia pseudomallei. Infect Immun 76 : 5402 5411.
85. Harding SV, Sarkar-Tyson M, Smither SJ, Atkins TP, Oyston PCF, Brown KA et al. (2007). The identification of surface proteins of Burkholderia pseudomallei. Vaccine 25 : 2664 2672. (Pubitemid 46420472)
86. Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M et al. (2007). Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect Immun 75 : 4173 4180. (Pubitemid 47206316)
87. Harris R, Paxman J (1982). A Higher Form of Killing: The Secret History of Chemical and Biological Warfare. Hill and Wang :
88. Harrison LM, Rallabhandi P, Michalski J, Zhou X, Steyert SR, Vogel SN et al. (2008). Vibrio cholerae flagellins induce Toll-like receptor 5-mediated interleukin-8 production through mitogen-activated protein kinase and NF-kappaB activation. Infect Immun 76 : 5524 5534.
89. He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L et al. (2007). Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine-induced immunity. J Infect Dis 196 : 1026 1032. (Pubitemid 47580297)
90. Heath DG, Anderson GW, Jr., Mauro JM, Welkos SL, Andrews GP, Adamovicz J et al. (1998). Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 : 1131 1137. (Pubitemid 28307882)
91. Hesselberth JR, Miller D, Robertus J, Ellington AD (2000). In vitro selection of RNA molecules that inhibit the activity of ricin A-chain. J Biol Chem 275 : 4937 4942. (Pubitemid 30108888)
92. Hu WG, Chau D, Wu J, Jager S, Nagata LP (2007). Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus. Vaccine 25 : 3210 3214. (Pubitemid 46505047)
93. Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K et al. (1996). Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64 : 1589 1594. (Pubitemid 26129820)
94. Ivanov MI, Noel BL, Rampersaud R, Mena P, Benach JL, Bliska JB (2008). Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1-Yersinia pestis. Infect Immun 76 : 5181 5190.
95. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR (1993). Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 61 : 4272 4279. (Pubitemid 23298584)
96. Jahrling PB, Fritz EA, Hensley LE (2005). Countermeasures to the bioterrorist threat of smallpox. Curr Mol Med 5 : 817 826.
97. Jahrling PB, Huggins JW, Ibrahim MS, Lawler JV, Martin JW (2007). Smallpox and related orthopoxviruses. In : Dembek ZF (ed.). Medical Aspects of Biological Warfare. Office of the Surgeon General and the Borden Institute :
98. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC et al. (2002). Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8 : 1019 1028. (Pubitemid 35256987)
99. Jiang XL, He ZM, Peng ZQ, Qi Y, Chen Q, Yu SY (2007). Cholera toxin B protein in transgenic tomato fruit induces systemic immune response in mice. Transgenic Res 16 : 169 175. (Pubitemid 46440609)
100. Jones RG, Liu Y, Rigsby P, Sesardic D (2008). An improved method for development of toxoid vaccines and antitoxins. J Immunol Methods 337 : 42 48.
101. Jones SM, Day F, Stagg AJ, Williamson ED (2000). Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 19 : 358 366. (Pubitemid 30621530)
102. Jones T, Adamovicz JJ, Cyr SL, Bolt CR, Bellerose N, Pitt LM et al. (2006). Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24 : 1625 1632. (Pubitemid 43238239)
103. Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J et al. (2008). Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother 52 : 1721 1727. (Pubitemid 351614665)
104. Julander JG, Bowen RA, Rao JR, Day C, Shafer K, Smee DF et al. (2008a). Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Res 80 : 309 315.
105. Julander JG, Skirpstunas R, Siddharthan V, Shafer K, Hoopes JD, Smee DF et al. (2008b). C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res 78 : 230 241.
106. Kang J, Lee MS, Watowich SJ, Gorenstein DG (2007). Combinatorial selection of a RNA thioaptamer that binds to Venezuelan equine encephalitis virus capsid protein. FEBS Lett 581 : 2497 2502. (Pubitemid 46764716)
107. Karunakaran R, Puthucheary SD (2007). Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials. Scand J Infect Dis 39 : 858 861. (Pubitemid 47470774)
108. Kende M, Tan X, Wlazlowski C, Williams R, Lindsey C, Del Giudice G (2007). Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72. Vaccine 25 : 3219 3227. (Pubitemid 46482754)
109. Kennedy JS, Greenberg RN (2009). IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 8 : 13 24.
110. Klas SD, Petrie CR, Warwood SJ, Williams MS, Olds CL, Stenz JP et al. (2008). A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine 26 : 5494 5502.
111. Klinman DM, Currie D, Lee G, Grippe V, Merkel T (2007). Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect 9 : 1478 1483. (Pubitemid 350016979)
112. Kozel TR, Thorkildson P, Brandt S, Welch WH, Lovchik JA, AuCoin DP et al. (2007). Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun 75 : 152 163. (Pubitemid 46047889)
113. Kummer LW, Szaba FM, Parent MA, Adamovicz JJ, Hill J, Johnson LL et al. (2008). Antibodies and cytokines independently protect against pneumonic plague. Vaccine 26 : 6901 6907.
114. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV et al. (1997). Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 126 : 257 263. (Pubitemid 27078773)
115. Lawton WD, Erdman RL, Surgalla MJ (1963). Biosynthesis and purification of V and W antigens in Pasteurella pestis. Tech Manuscr US Army Biol Lab 21 : 1 15.
116. Legutki JB, Nelson M, Titball R, Galloway DR, Mateczun A, Baillie LW (2007). Analysis of peptide mimotopes of Burkholderia pseudomallei exopolysaccharide. Vaccine 25 : 7796 7805. (Pubitemid 47595372)
117. Lemley PV, Amanatides P, Wright DC (1994). Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 13 : 417 421. (Pubitemid 24351544)
118. Little SF (2005). Anthrax vaccines: a development update. BioDrugs 19 : 233 245.
119. Little SF, Knudson GB (1986). Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52 : 509 512.
120. Liu WT, Hsu HL, Liang CC, Chuang CC, Lin HC, Liu YT (2007). A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen. FEMS Immunol Med Microbiol 51 : 58 69.
121. McConnell MJ, Hanna PC, Imperiale MJ (2007). Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol Ther 15 : 203 210.
122. McHugh CA, Tammariello RF, Millard CB, Carra JH (2004). Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci 13 : 2736 2743.
123. Manayani DJ, Thomas D, Dryden KA, Reddy V, Siladi ME, Marlett JM et al. (2007). A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. Plos Pathog 3 : 1422 1431. (Pubitemid 350085607)
124. Marmion B (2007). Q fever: the long journey to control by vaccination. Med J Aust 186 : 164 166. (Pubitemid 46380862)
125. Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP (2008). Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26 : 581 588.
126. Maurin M, Raoult D (1999). Q fever. Clin Microbiol Rev 12 : 518 553. (Pubitemid 29484745)
127. Mayr A, Stickl H, Muller HK, Danner K, Singer H (1978). [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol [B] 167 : 375 390. (Pubitemid 9145179)
128. Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR et al. (2005). Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339 : 164 175. (Pubitemid 41169785)
129. Mett V, Lyons J, Musiychuk K, Chichester JA, Brasil T, Couch R et al. (2007). A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 25 : 3014 3017. (Pubitemid 46482733)
130. Michel G, Petrakova O, Atasheva S, Frolov I (2007). Adaptation of Venezuelan equine encephalitis virus lacking 51-nt conserved sequence element to replication in mammalian and mosquito cells. Virology 362 : 475 487. (Pubitemid 46678158)
131. Miller RA, Oseroff AR, Stratte PT, Levy R (1983). Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62 : 988 995. (Pubitemid 14237319)
132. Mizel SB, Graff AH, Sriranganathan N, Ervin S, Lees CJ, Lively MO et al. (2009). Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol 16 : 21 28.
133. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M et al. (2004). ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8 (Suppl. 2 S31 S44. (Pubitemid 39445966)
134. Montecucco C, Molgo J (2005). Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 5 : 274 279. (Pubitemid 40674251)
135. Moodie CE, Thompson HA, Meltzer MI, Swerdlow DL (2008). Prophylaxis after exposure to Coxiella burnetii. Emerg Infect Dis 14 : 1558 1566.
136. Morris SR (2007). Development of a recombinant vaccine against aerosolized plague. Vaccine 25 : 3115 3117. (Pubitemid 46482764)
137. Murphy BS, Wulff CR, Garvy BA, Straley SC (2007). Yersinia pestis YadC: a novel vaccine candidate against plague. Adv Exp Med Biol 603 : 400 414.
138. Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE et al. (2008). Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 79 : 121 127.
139. Nygren E, Holmgren J, Attridge SR (2008). Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. Vaccine 26 : 6784 6790.
140. O'Brien L (2007). Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs. Antiviral Res 75 : 20 29. (Pubitemid 46613790)
141. Ochoa-Reparaz J, Sentissi J, Trunkle T, Riccardi C, Pascual DW (2007). Attenuated Coxiella burnetii phase II causes a febrile response in gamma interferon knockout and toll-like receptor 2 knockout mice and protects against reinfection. Infect Immun 75 : 5845 5858. (Pubitemid 350207824)
142. Olson KB (1999). Aum Shinrikyo: once and future threat? Emerg Infect Dis 5 : 513 516.
143. Olson MA, Carra JH, Roxas-Duncan V, Wannemacher RW, Smith LA, Millard CB (2004). Finding a new vaccine in the ricin protein fold. Protein Eng Des Sel 17 : 391 397. (Pubitemid 39093520)
144. Oszvald M, Kang TJ, Tomoskozi S, Jenes B, Kim TG, Cha YS et al. (2008). Expression of cholera toxin B subunit in transgenic rice endosperm. Mol Biotechnol 40 : 261 268.
145. Paessler S, Yun NE, Judy BM, Dziuba N, Zacks MA, Grund AH et al. (2007). Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. Virology 367 : 307 323. (Pubitemid 47494531)
146. Paessler S, Rijnbrand R, Stein DA, Ni H, Yun NE, Dziuba N et al. (2008). Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology 376 : 357 370.
147. Parker NR, Barralet JH, Bell AM (2006). Q fever. Lancet 367 : 679 688.
148. Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC et al. (2008). Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 77 : 39 49.
149. Parola P, Raoult D (2007). Rickettsial Diseases. CRC Press :
150. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME et al. (2007). Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25 : 1513 1525. (Pubitemid 46074296)
151. Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK (2007). Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol 81 : 8774 8783. (Pubitemid 47242850)
152. Perkins SD, Williams AJ, O'Brien LM, Laws TR, Phillpotts RJ (2008). CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product. Viral Immunol 21 : 451 457.
153. Pettineo C, Aitchison R, Leikin SM, Vogel SN, Leikin JB (2009). Biological and chemical weapons of mass destruction: updated clinical therapeutic countermeasures since 2003. Am J Ther 16 : 35 43.
154. Philipovskiy AV, Smiley ST (2007). Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun 75 : 878 885.
155. Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR (2008). Recombinant holotoxoid vaccine against botulism. Infect Immun 76 : 437 442. (Pubitemid 351428096)
156. Pittman PR, Gibbs PH, Cannon TL, Friedlander AM (2001). Anthrax vaccine: short-term safety experience in humans. Vaccine 20 : 972 978.
157. Pittman PR, Coonan KM, Gibbs PH, Scott HM, Cannon TL, McKee KT, Jr. (2004). Long-term health effects of repeated exposure to multiple vaccines. Vaccine 23 : 525 536.
158. Poland JD (2009). Plague Manual: Epidemiology, Distribution, Surveillance and Control. World Health Organization :
159. Powell BS, Andrews GP, Enama JT, Jendrek S, Bolt C, Worsham P et al. (2005). Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21 : 1490 1510. (Pubitemid 41443005)
160. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA et al. (2007). Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 25 : 231 238. (Pubitemid 44856084)
161. Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR et al. (2007). Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 51 : 4118 4124. (Pubitemid 350057813)
162. Rao V, Hinz ME, Roberts BA, Fine D (2006). Toxicity assessment of Venezuelan Equine Encephalitis virus vaccine candidate strain V3526. Vaccine 24 : 1710 1715. (Pubitemid 43238249)
163. Reed RP (1998). Castor oil seed poisoning: a concern for children. Med J Aust 168 : 423 424.
164. Rhie GE, Jung HM, Kim BS, Mekalanos JJ (2008a). Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit. Vaccine 26 : 5443 5448.
165. Rhie GE, Jung HM, Park J, Kim BS, Mekalanos JJ (2008b). Construction of cholera toxin B subunit-producing Vibrio cholerae strains using the Mariner-FRT transposon delivery system. FEMS Immunol Med Microbiol 52 : 23 28.
166. Robinson JP, Leitenberg M (1971). The Rise in CB Weapons. The Problem of Chemical and Biological Warfare. Almquist & Wiksells :
167. Rosales-Mendoza S, Soria-Guerra RE, Lopez-Revilla R, Moreno-Fierros L, Alpuche-Solis AG (2008). Ingestion of transgenic carrots expressing the Escherichia coli heat-labile enterotoxin B subunit protects mice against cholera toxin challenge. Plant Cell Rep 27 : 79 84. (Pubitemid 350242818)
168. Rosas CT, Paessler S, Ni H, Osterrieder N (2008). Protection of mice by equine herpesvirus type 1 based experimental vaccine against lethal Venezuelan equine encephalitis virus infection in the absence of neutralizing antibodies. Am J Trop Med Hyg 78 : 83 92. (Pubitemid 351844500)
169. Roy SK, Hossain MJ, Khatun W, Chakraborty B, Chowdhury S, Begum A et al. (2008). Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial. BMJ 336 : 266 268. (Pubitemid 351251628)
170. Russell-Lodrigue KE, Zhang GQ, McMurray DN, Samuel JE (2006). Clinical and pathologic changes in a guinea pig aerosol challenge model of acute Q fever. Infect Immun 74 : 6085 6091.
171. Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, Siirin M et al. (2007). Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 76 : 768 773. (Pubitemid 351627722)
172. Schild S, Nelson EJ, Camilli A (2008). Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun 76 : 4554 4563.
173. Schneemann A, Manchester M (2009). Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol 4 : 35 43.
174. Scorpio A, Blank TE, Day WA, Chabot DJ (2006). Anthrax vaccines: Pasteur to the present. Cell Mol Life Sci 63 : 2237 2248. (Pubitemid 44653037)
175. Scorpio A, Chabot DJ, Day WA, O'Brien DK, Vietri NJ, Itoh Y et al. (2007). Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob Agents Chemother 51 : 215 222. (Pubitemid 46047709)
176. Scorpio A, Tobery SA, Ribot WJ, Friedlander AM (2008). Treatment of experimental anthrax with recombinant capsule depolymerase. Antimicrob Agents Chemother 52 : 1014 1020. (Pubitemid 351358382)
177. Segal G, Feldman M, Zusman T (2005). The Icm/Dot type-IV secretion systems of Legionella pneumophila and Coxiella burnetii. FEMS Microbiol Rev 29 : 65 81. (Pubitemid 40094766)
178. Selvam P, Vijayalakshimi P, Smee DF, Gowen BB, Julander JG, Day CW et al. (2007). Novel 3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses. Antivir Chem Chemother 18 : 301 305. (Pubitemid 350220749)
179. Sharma A, Raviv Y, Puri A, Viard M, Blumenthal R, Maheshwari RK (2007). Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys Res Commun 358 : 392 398. (Pubitemid 46755721)
180. Sharma MK, Jani D, Thungapathra M, Gautam JK, Meena LS, Singh Y et al. (2008a). Expression of accessory colonization factor subunit A (ACFA) of Vibrio cholerae and ACFA fused to cholera toxin B subunit in transgenic tomato (Solanum lycopersicum). J Biotechnol 135 : 22 27.
181. Sharma MK, Singh NK, Jani D, Sisodia R, Thungapathra M, Gautam JK et al. (2008b). Expression of toxin co-regulated pilus subunit A (TCPA) of Vibrio cholerae and its immunogenic epitopes fused to cholera toxin B subunit in transgenic tomato (Solanum lycopersicum). Plant Cell Rep 27 : 307 318.
182. da Silva AP, Unks D, Lyu SC, Ma J, Zbozien-Pacamaj R, Chen X et al. (2008). In vitro and in vivo antimicrobial activity of granulysin-derived peptides against Vibrio cholerae. J Antimicrob Chemother 61 : 1103 1109. (Pubitemid 351524457)
183. Simpson AJH, Suputtamongkol Y, Smith MD, Angus BJ, Rajanuwong A, Wuthiekanun V et al. (1999). Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 29 : 381 387. (Pubitemid 29380204)
184. Simpson LL (2004). Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44 : 167 193. (Pubitemid 38263838)
185. Sinclair HR, Smejkal CW, Glister C, Kemp F, van den Heuvel E, de Slegte J et al. (2008). Sialyloligosaccharides inhibit cholera toxin binding to the GM1 receptor. Carbohydr Res 343 : 2589 2594.
186. Singh BR (2000). Intimate details of the most poisonous poison. Nat Struct Biol 7 : 617 619.
187. Singh BR (2006). Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox Res 9 : 73 92.
188. Sivalingam SP, Sim SH, Jasper LCW, Wang D, Liu Y, Ooi EE (2008). Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole. Journal of Antimicrobial. Chemotherapy 61 : 674 678. (Pubitemid 351321146)
189. Slifka MK (2005). The future of smallpox vaccination: is MVA the key? Med Immunol 4 : 2.
190. Smallshaw JE, Firan A, Fulmer JR, Ruback SL, Ghetie V, Vitetta ES (2002). A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 20 : 3422 3427. (Pubitemid 35245826)
191. Smallshaw JE, Richardson JA, Pincus S, Schindler J, Vitetta ES (2005). Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine 23 : 4775 4784. (Pubitemid 41557328)
192. Smallshaw JE, Richardson JA, Vitetta ES (2007). RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 25 : 7459 7469.
193. Smart JK (1997). Histroy of chemical and biological warfare: an American perspective. In : Sidell FR, Takafuji ET, Franz DR (eds). Medical Aspects of Chemical and Biological Warfare. Borden Institute, Walter Reed Army Medical Center :
194. Smith LA, Rusnak JM (2007). Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27 : 303 318.
195. Sofer-Podesta C, Ang J, Hackett NR, Senina S, Perlin D, Crystal RG et al. (2009). Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun 77 : 1561 1568.
196. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA (1996). Development of novel vaccines against anthrax in man. J Biotechnol 44 : 155 160. (Pubitemid 26056574)
197. Stokes MG, Titball RW, Neeson BN, Galen JE, Walker NJ, Stagg AJ et al. (2007). Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun 75 : 1827 1834.
198. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, Dance DAB, Smith MD, Wuthiekanun V et al. (1994). Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 19 : 846 853. (Pubitemid 24368819)
199. Tan CK, Chan KS, Yu WL, Chen CM, Cheng KC (2007). Successful treatment of life-threatening melioidosis with activated protein C and meropenem. J Microbiol Immunol Infect 40 : 83 87.
200. Tan GYG, Liu Y, Sivalingam SP, Sim SH, Wang D, Paucod JC et al. (2008). Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. J Med Microbiol 57 : 508 515. (Pubitemid 351537028)
201. Thakurta P, Bhowmik P, Mukherjee S, Hajra TK, Patra A, Bag PK (2007). Antibacterial, antisecretory and antihemorrhagic activity of Azadirachta indica used to treat cholera and diarrhea in India. J Ethnopharmacol 111 : 607 612. (Pubitemid 46617104)
202. Torok TJ, Tauxe RV, Wise RP, Livengood JR, Sokolow R, Mauvais S et al. (1997). A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 278 : 389 395. (Pubitemid 27327457)
203. Tsironi M, Andriopoulos P, Fokas S, Nikokiris G, Mantzourani M, Assimakopoulos G et al. (2005). Acute Q fever lobar pneumonia: a case report. J Infect 51. (Pubitemid 41554846)
204. Turnbull PC (2002). Introduction: anthrax history, disease and ecology. Curr Top Microbiol Immunol 271 : 1 19.
205. Uddowla S, Freytag LC, Clements JD (2007). Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine 25 : 7984 7993. (Pubitemid 47632994)
206. Valero N, MarinaEspina L, Bonilla E, Mosquera J (2007). Melatonin decreases nitric oxide production and lipid peroxidation and increases interleukin-1 beta in the brain of mice infected by the Venezuelan equine encephalomyelitis virus. J Pineal Res 42 : 107 112. (Pubitemid 46233054)
207. Vitetta ES, Smallshaw JE, Coleman E, Jafri H, Foster C, Munford R et al. (2006). A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci USA 103 : 2268 2273. (Pubitemid 43271659)
208. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L et al. (2006). Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24 : 2065 2070. (Pubitemid 43255148)
209. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, Stein SL et al. (2008). Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Infect Clin Dis 46 : 1555 1561. (Pubitemid 351706737)
210. Waag DM (2007). Coxiella burnetii: host and bacterial responses to infection. Vaccine 25 : 7288 7295. (Pubitemid 47484005)
211. Waag DM, England MJ, Bolt CR, Williams JC (2008). Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii. Clin Vaccine Immunol 15 : 1505 1512.
212. Wang E, Petrakova O, Adams AP, Aguilar PV, Kang W, Paessler S et al. (2007a). Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. Vaccine 25 : 7573 7581. (Pubitemid 47503491)
213. Wang Y, Guo L, Zhao K, Chen J, Feng J, Sun Y et al. (2007b). Novel chimeric anti-ricin antibody C4C13 with neutralizing activity against ricin toxicity. Biotechnol Lett 29 : 1811 1816. (Pubitemid 350043610)
214. Wang JY, Roehrl MH (2005). Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med Immunol 4 : 4.
215. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA (2007). Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25 : 4273 4282.
216. Welkos SL, Friedlander AM (1988). Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog 5 : 127 139.
217. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS et al. (2003). Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 9 : 1125 1130. (Pubitemid 37173695)
218. Williams TL, Jenkins AT (2008). Measurement of the binding of cholera toxin to GM1 gangliosides on solid supported lipid bilayer vesicles and inhibition by europium (III) chloride. J Am Chem Soc 130 : 6438 6443.
219. Williamson ED (2001). Plague vaccine research and development. J Appl Microbiol 91 : 606 608.
220. Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL et al. (2005). Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73 : 3598 3608. (Pubitemid 40745904)
221. Willis B, Eubanks LM, Dickerson TJ, Janda KD (2008). The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl 47 : 8360 8379.
222. World Health Organization (2008). Cholera. Fact Sheet N°107 WWW document]. URL: http://www.who.int/en.
223. Worsham PL, McGovern TW, Vietri NJ, Friedlander AM (2007). Plague. In : Dembek ZF (ed.). Medical Aspects of Biological Warfare. Office of the Surgeon General and the Borden Institute :
224. Wu JQ, Barabe ND, Chau D, Wong C, Rayner GR, Hu WG et al. (2007a). Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine. Vaccine 25 : 4368 4375. (Pubitemid 46705422)
225. Wu JQ, Barabe ND, Huang YM, Rayner GA, Christopher ME, Schmaltz FL (2007b). Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology 369 : 206 213.
226. Yamanaka H, Hoyt T, Yang X, Golden S, Bosio CM, Crist K et al. (2008). A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun 76 : 4564 4573.
227. Yan M, Liu G, Diao B, Qiu H, Zhang L, Liang W et al. (2007). A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection. Vaccine 25 : 4046 4055. (Pubitemid 46628986)
228. Yang X, Hinnebusch BJ, Trunkle T, Bosio CM, Suo Z, Tighe M et al. (2007). Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol 178 : 1059 1067. (Pubitemid 46095179)
229. Yu YZ, Sun ZW, Wang S, Yu WY (2007a). High-level expression of the Hcc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen. Sheng Wu Gong Cheng Xue Bao 23 : 812 817.
230. Yu YZ, Zhang SM, Sun ZW, Wang S, Yu WY (2007b). Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 25 : 8843 8850. (Pubitemid 350192055)
231. Yu YZ, Li N, Zhu HQ, Wang RL, Du Y, Wang S et al. (2009). The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 27 : 2816 2822.
232. Yuki Y, Kiyono H (2008). MucoRice: development of rice-based oral vaccine. Nihon Rinsho Meneki Gakkai Kaishi 31 : 369 374.
233. Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, Smith LA (2007). Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 25 : 7540 7548. (Pubitemid 47503495)
234. Zhang G, Russell-Lodrigue KE, Andoh M, Zhang Y, Hendrix LR, Samuel JE (2007). Mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection in BALB/c mice. J Immunol 179 : 8372 8380.
235. Zhang RG, Scott DL, Westbrook ML, Nance S, Spangler BD, Shipley GG et al. (1995). The three-dimensional crystal structure of cholera toxin. J Mol Biol 251 : 563 573.
236. Zhang Y, Qiu J, Zhou Y, Farhangfar F, Hester J, Lin AY et al. (2008). Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Vaccine 26 : 614 622.
237. Zou N, Newsome T, Li B, Tsai S, Lo SC (2007). Human single-chain Fv antibodies against Burkholderia mallei and Burkholderia pseudomallei. Exp Biol Med 232 : 550 556. (Pubitemid 46524477)